A BIOPHARMACEUTICAL COMPANY DEVELOPING A DIVERSE PORTFOLIO OF WELL-CHARACTERIZED DRUGS FOR RARE DISEASES

EIGER BIOPHARMACEUTICALS

ABOUT EIGER

MANAGEMENT TEAM

BOARD OF DIRECTORS

SCIENTIFIC ADVISORS

CORPORATE PRESENTATION

EXPANDED ACCESS POLICY

CONTACT US

LATE STAGE PIPELINE: VALUE CREATING CATALYSTS

EIGER'S PROGERIA PLEDGE

RARE DISEASES CAMPAIGN

NEWS AND EVENTS

PRESS RELEASES

CALENDAR OF EVENTS

EIGER'S PROGERIA PROMISE

INVESTOR RELATIONS

INVESTOR NEWS

INVESTOR CALENDAR

INVESTOR RELATIONS

INVESTOR HOME

STOCK INFORMATION

FINANCIAL INFORMATION

INVESTOR PRESENTATIONS

CORPORATE GOVERNANCE

SHAREHOLDER SERVICES

ANALYST COVERAGE

STOCK PRICE

Prevailing Over HDV

HEPATITIS DELTA (HDV)

ABOUT HDV

ABOUT LONAFARNIB

ABOUT PEGYLATED-INTERFERON-LAMBDA

LONAFARNIB, PEGYLATED-INTERFERON LAMBDA & HDV RESOURCES

LONAFARNIB CLINICAL STUDIES

PEGYLATED-INTERFERON-LAMBDA CLINICAL STUDIES

PUBLICATIONS & PRESENTATIONS

PROFESSIONAL & PATIENT RESOURCES

Rising Above Post-bariatric Hypoglycemia

POST-BARIATRIC HYPOGLYCEMIA

ABOUT POST-BARIATRIC HYPOGLYCEMIA

ABOUT AVEXITIDE

GLP-1 RECEPTOR ANTAGONISM

AVEXITIDE & POST-BARIATRIC HYPOGLYCEMIA RESOURCES

AVEXITIDE CLINICAL STUDIES

PUBLICATIONS & PRESENTATIONS

PROFESSIONAL & PATIENT RESOURCES

Overcoming Hutchinson-Gilford Progeria Syndrome

Meet the Kids

HUTCHINSON-GILFORD PROGERIASYNDROME (PROGERIA)

ABOUT HUTCHINSON-GILFORD PROGERIASYNDROME (PROGERIA)

ABOUT LONAFARNIB FOR PROGERIA

EIGER'S PARTNERSHIP WITH THE PROGERIA RESEARCH FOUNDATION (PRF)

LONAFARNIB AND PROGERIA RESOURCES/PUBLICATIONS

LONAFARNIB CLINICAL STUDIES IN PROGERIA

PUBLICATIONS AND PRESENTATIONS

PROFESSIONAL AND PATIENT RESOURCES

Professional and Patient Resources

Post-bariatric Hypoglycemia

HUTCHINSON-GILFORD PROGERIA
SYNDROME (PROGERIA)

ABOUT HUTCHINSON-GILFORD PROGERIA
SYNDROME (PROGERIA)